1. Home
  2. Live Updates
  3. Idiopathic hypersomnia

Live Breaking News & Updates on Idiopathic hypersomnia

Stay informed with the latest breaking news from Idiopathic hypersomnia on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Idiopathic hypersomnia and stay connected to the pulse of your community

Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy

Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United-kingdom , United-states , Americans , Luis-sanay , Jeffreym-dayno , Epygenix-company-presentation , European-medicines-agency , Epygenix-therapeutics-inc , Nasdaq , Exchange-commission , European-union , Share-repurchase-program

Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its ...

WAKIX® (pitolisant) Net Revenue of $154.6 Million for First Quarter 2024; ~30% Growth Year-over-Year

United-kingdom , United-states , Americans , Luis-sanay , Jeffreym-dayno , Epygenix-therapeutics-inc , Exchange-commission , Epygenix-company-presentation , Share-repurchase-program , European-union , European-medicines-agency , Harmony-biosciences-holdings-inc

Smart Living: Unexplained sleepiness study

About a third of people in the United States don't get enough sleep, according to the Centers for Disease Control and Prevention

United-states , Leandre-schoeman , Centers-for-disease , University-of-wisconsin , Disease-control , Sleep-consultant-leandre-schoeman , Idiopathic-hypersomnia ,

US Woman Who Felt Tired All The Time Diagnosed With Rare Sleeping Disorder

A 26-year-old US woman who felt tired all the time and found herself dozing off at school and in dance classes growing up has been diagnosed with a rare chronic sleeping disorder.

New-york , United-states , United-kingdom , Alyssa-davis , New-york-post , Groundhog-day- , Sleep-foundation , Sleeping-disorder , Idiopathic-hypersomnia , Rare-sleeping-disorder , Woman-who-felt-tired-all-the-time-diagnosed-with-sleeping-disorder , Us-news

Alkermes plc: Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia

Alkermes plc: Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Dublin , Ireland , United-states , Massachusetts , Athlone , Westmeath , Waltham , Ohio , American , Ron-grunstein , Sandy-coombs , Gretchen-murphy

Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia

Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Dublin , Ireland , United-states , Massachusetts , Waltham , Ohio , Athlone , Westmeath , American , Ron-grunstein , Sandy-coombs , Gretchen-murphy

Alkermes' Sleeping Disorder Studies' Data Look Excellent, Analyst Says - Alkermes (NASDAQ:ALKS)

ALKS 2680 reports positive results in narcolepsy & idiopathic hypersomnia study. Statistically significant improvements in sleep latency were observed across all doses tested. Phase 2 study for NT2 patients is planned for 2nd half of 2024. Jefferies raises price target & probability of success for ALKS-2680.

Alkermes , Wakefulness-test , Narcolepsy-type , Idiopathic-hypersomnia ,

I'm exhausted all the time — doctors called me lazy until they discovered my rare condition

"It’s like being trapped in the 'Groundhog Day' movie — except instead of reliving the same day, I just relive the same exhaustion,” lamented Alyssa Davis.

North-carolina , United-states , Alyssa-davis , Drug-administration , Groundhog-day- , Sleep-foundation , Idiopathic-hypersomnia , Lyssa-davis , Leep-study , Leep-disorder , Ondition , Leep-paralysis

KP1077 Is Safe, Tolerable for Improving Idiopathic Hypersomnia Symptoms

A phase 2 trial found KP1077 provides clinically meaningful benefits for idiopathic hypersomnia.

United-states , American , Christopher-drake , Henry-ford-health-christopher-drake , American-academy-of-sleep-medicine , Drug-administration , Us-drug-enforcement-agency , Henry-ford-health , Zevra-therapeutics , American-academy , Orphan-drug-designation , Enforcement-agency

Zevra Therapeutics Reports Fourth Quarter and Full Year

Zevra Therapeutics Reports Fourth Quarter and Full Year
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United-states , France , French , Neilf-mcfarlane , Nichol-ochsner , Adannag-alexander , Drug-administration , Exchange-commission , Access-program , Company-expanded-access-program , European-medicines-agency , Company-annual-report-on-form